The study on safe and effective dose of daunomycin for prevention of posterio capsule opacification

马进,陈大本,李涤臣,陶仪声,郁佳,张淑娟

DOI: https://doi.org/10.3760/cma.j.issn.2095-0160.2002.06.012

2002-01-01

Abstract:Objective: To investigate the safe and effective concentration of daunomycin as a preventer of posterior capsule opacification (PCO) in animal experiments. Methods: 5-20 mg/L daunomycin was infused into lens capsular bag for 10 minutes during ECCE operation on rabbits eyes. At the 1st week after operation, response of corneal endothelial cells, iris and ciliary body were observed with light and electron microscope. 1 month later, the difference of cell density in the lens epithelium of each group exposed to different drug concentration was studied. The safe and effective close of daunomycin into the anterior chamber was obtained. Results: The concentrations of 5-20 mg/L could effectively inhibit the proliferation of the anterior capsular epithelium in a dose-dependent manner. 5 mg/L of daunomycin could effectively inhibit the proliferation of the anterior capsular epithelium without toxicity to adjacent ocular tissues. The concentrations of 10-20 mg/L could cause microchanges in corneal endothelial cell and acute inflammation of iris and ciliary body; 20 mg/L daunomycin could damage ocular surface tissues. Conclusion: The safe and effective concentration of daunomucin in preventing the posterior capsule opacification is 5 mg/L. This close may be valuable for the prevention of PCO during clinical application.